Nkarta, Inc. (NKTX)
Drugs • Health Care
June 26, 2026 Nkarta, Inc. to Showcase Innovative CAR-NK Cell Therapy at H.C. Wainwright Conference Nkarta, Inc. will present its CAR-NK cell therapy aimed at treating autoimmune diseases during the H.C. Wainwright Conference on June 30, 2026. President Nadir Mahmood will share insights into the innovative therapy's potential to enhance patient outcomes, with a webcast available for those unable to attend.
April 15, 2026 Nkarta, Inc. Expands Clinical Access with FDA Agreement on NKX019 Outpatient Dosing Nkarta, Inc. has secured an FDA agreement to allow outpatient dosing of its NKX019 CAR-NK cell therapy, significantly improving patient access and experience. The agreement facilitates partnerships with community rheumatology centers and expands clinical trials to include rheumatoid arthritis, optimizing treatment options for patients.
April 09, 2026 Nkarta, Inc. to Showcase Innovations in Autoimmune Therapies at Needham Conference Nkarta, Inc. will present its innovative NK cell therapies for autoimmune diseases at the 25th Annual Needham Virtual Healthcare Conference. CEO Paul Hastings and President Nadir Mahmood will lead discussions on the state of cell therapy and Nkarta's investigational CAR-NK cell therapy.
March 25, 2026 Nkarta, Inc. Reports Financial Results for 2025: A Year of Strategic Advances and Clinical Developments Nkarta, Inc. reported significant advances in 2025, including clinical trials for NKX019 targeting autoimmune diseases and a robust financial position, projecting growth through 2029. Key highlights include strategic restructuring and ongoing dose escalation in clinical programs.
March 25, 2026 Nkarta, Inc. Reports 2025 Annual Results: A Year of Clinical Advances and Financial Adjustments Nkarta, Inc. reports significant clinical advancements in its NKX019 trials for autoimmune diseases while navigating financial losses of $104 million in 2025. A strategic workforce reduction aims to enhance operational efficiency as the company continues to focus on innovative therapies.
February 27, 2026 Nkarta, Inc. Set to Engage Investors as It Participates in Upcoming Conferences Nkarta, Inc. is set to participate in two key investor conferences in March 2026, including the TD Cowen and Leerink Global Healthcare Conferences. The company will present its advancements in NK cell therapies aimed at treating autoimmune diseases, providing crucial updates to investors and stakeholders.
December 02, 2025 Nkarta, Inc. Set to Showcase Innovations at Evercore Healthcare Conference Nkarta, Inc. will present its advancements in NK cell therapies at the Evercore Healthcare Conference on December 4, 2025. The company focuses on innovative outpatient treatments for autoimmune diseases, enhancing accessibility and patient care.
November 10, 2025 Nkarta, Inc. Reports Third Quarter 2025 Financial Results and Clinical Advancements Nkarta, Inc. reported its Q3 2025 financial results, highlighting advancements in its NKX019 trials aimed at treating autoimmune diseases. The company has engaged with the FDA to enhance trial efficiency and has made improvements to its treatment regimen, positioning itself for future success in clinical development.
November 10, 2025 Nkarta, Inc. Reports Q3 2025 Financial Results: Strategic Shifts and Clinical Advancements Nkarta, Inc. reveals its Q3 2025 financial results, showcasing a reduced net income loss and strategic workforce adjustments. The ongoing NKX019 clinical trials reflect the company’s commitment to innovation in autoimmune disease treatments.
October 30, 2025 Nkarta, Inc. Gears Up for November Investor Conferences Nkarta, Inc. is set to participate in two major investor conferences in November 2025, focusing on its NK cell therapies for autoimmune diseases. The events will feature leadership discussions on the company's pipeline and strategic vision, with webcasts available for those unable to attend.
October 22, 2025 Nkarta, Inc. Showcases Innovative NK Cell Therapy at ACR Convergence 2025 Nkarta, Inc. unveiled its innovative NK cell therapy, NKX019, at ACR Convergence 2025, showcasing significant clinical data on B-cell depletion. This therapy aims to address unmet needs in treating autoimmune diseases and non-Hodgkin lymphoma. The company’s presentation highlights a novel approach with potential for profound impacts in the field.
August 12, 2025 Nkarta, Inc. Reports Q2 2025 Financial Results: Navigating Challenges and Opportunities Nkarta, Inc. reported a Q2 2025 net loss of $22.97 million, showing improved cost management. The company is focusing on its NKX019 candidate while navigating financial challenges and seeking additional funding.
May 14, 2025 Nkarta, Inc. Q1 2025 Financial Report: Navigating Challenges Amid Clinical Progress Nkarta, Inc.'s Q1 2025 financial report reveals significant losses amid clinical advancements in NK cell therapies. The company is focusing on strategic realignment and managing operational costs while aiming for future revenue through innovative therapies.
April 01, 2025 Nkarta, Inc. Announces Participation in Key Investor Conference Nkarta, Inc. will participate in the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025, highlighting its advancements in NK cell therapies. The event features a fireside chat with executives and offers a webcast for those unable to attend live, ensuring broad access to insights on the company's innovative treatments.
March 26, 2025 Nkarta, Inc. Reports 2024 Annual Financial Results: A Year of Challenges and Strategic Realignment Nkarta, Inc. reports a net income loss of $108.7 million in 2024, showing slight financial improvement. The company focuses on NKX019 for autoimmune diseases and has initiated new clinical trials while restructuring to manage costs effectively.
March 26, 2025 Nkarta, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results Nkarta, Inc. has reported its financial results for Q4 and the full year 2024, highlighting progress in its NKX019 therapy for autoimmune diseases. Despite a workforce reduction, the company remains optimistic about its clinical programs and financial stability, with substantial cash reserves to support future operations.
February 25, 2025 Nkarta, Inc. Gears Up for March Investor Conferences Nkarta, Inc. is set to participate in two major investor conferences in March 2025, aimed at highlighting its progress in NK cell therapies. The events will provide an opportunity for the company to engage with investors and share insights on its innovative treatments for autoimmune diseases.
February 13, 2025 SWOT Analysis of Nkarta, Inc. in 2025 This SWOT analysis of Nkarta, Inc. highlights its competitive advantages, including proprietary NK cell therapies and strong regulatory relationships. However, challenges such as financial instability and intense market competition could affect its growth trajectory in 2025.
November 07, 2024 Nkarta, Inc. Releases Q3 2024 Financial Results: Key Insights and Developments Nkarta, Inc. reported a net loss of $28.34 million in Q3 2024, reflecting increased R&D investments. The company is advancing its NK-cell therapies, focusing on clinical trials for autoimmune diseases.
August 13, 2024 Nkarta, Inc. Releases Q2 2024 Financial Results: A Steady Path in Clinical Development Nkarta, Inc. reports a reduced net loss for Q2 2024, reflecting strategic advancements in clinical trials. The company focuses on R&D for NK cell therapies while managing operational costs effectively.
May 09, 2024 Nkarta, Inc. Reports Q1 2024 Financial Results: A Step Forward Amid Challenges Nkarta, Inc. reported a $29.51 million net loss for Q1 2024, showing improved cost management and a strong liquidity position. The company continues to invest in NK-cell therapies while navigating clinical development challenges.
March 21, 2024 Nkarta, Inc. Reports 2023 Annual Financial Results: A Year of Growth Amid Challenges Nkarta, Inc. reported a net income loss of $117.5 million in 2023, primarily due to increased R&D expenses. Despite challenges, the FDA cleared its IND application for NKX019, marking a significant milestone. The company is focused on securing funding to advance its innovative NK cell therapies.